We are live on ! Find out more
SFM

Sphera Funds Management Portfolio holdings

AUM $630M
1-Year Est. Return 108.65%
This Fund
S&P 500
This Quarter Est. Return
+32.7%
1 Year Est. Return
+108.65%
3 Year Est. Return
+217.64%
5 Year Est. Return
+342.91%
10 Year Est. Return
+2,254.45%
AUM
$1.21B
AUM Growth
+$566M
Cap. Flow
+$396M
Cap. Flow %
32.65%
Top 10 Hldgs %
61.2%
Holding
106
New
26
Increased
22
Reduced
28
Closed
20

Top Buys

Rank Stock Value
1
SNY icon
Sanofi
SNY
+$20.6M
2
BMRN icon
BioMarin Pharmaceuticals
BMRN
+$19M
3
NVS icon
Novartis
NVS
+$17.9M
4
ACAD icon
Acadia Pharmaceuticals
ACAD
+$11.6M
5
NVO
Novo Nordisk
NVO
+$10.5M

Top Sells

Rank Stock Value
1
CELG
Celgene Corp
CELG
+$24.8M
2
ARQL
Arqule Inc
ARQL
+$20.7M
3
GILD icon
Gilead Sciences
GILD
+$13.3M
4
BMY icon
Bristol-Myers Squibb
BMY
+$11.2M
5
SRPT icon
Sarepta Therapeutics
SRPT
+$10.9M

Sector Composition

Rank Sector Weight
1 Healthcare 52.36%
2 Technology 6.25%
3 Industrials 0.98%
4 Consumer Discretionary 0.93%
5 Communication Services 0.45%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
TUFN
101
DELISTED
Tufin Software Technologies Ltd.
TUFN
– –
-12,231
Closed -$201K
DRNA
102
DELISTED
Dicerna Pharmaceuticals, Inc.
DRNA
– –
-565,000
Closed -$8.11M
CHMA
103
DELISTED
Chiasma, Inc. Common Stock
CHMA
– –
-990,000
Closed -$4.9M
PRVL
104
DELISTED
Prevail Therapeutics Inc. Common Stock
PRVL
– –
-90,217
Closed -$1.11M
HSACU
105
DELISTED
Health Sciences Acquisitions Corporation Units
HSACU
– –
-100,000
Closed -$1.07M
CELG
106
DELISTED
Celgene Corp
CELG
– –
-250,000
Closed -$24.8M
1 2 3 4
5

Similar funds

VIM
Vancity Investment Management Vancouver, British Columbia, Canada $629M AUM 2.49% 1-Year Est. Return
KCMH
Keywise Capital Management (HK) Hong Kong $630M AUM 81.01% 1-Year Est. Return
FCFC
First Commonwealth Financial Corp Indiana, Pennsylvania $629M AUM 20.47% 1-Year Est. Return
BI
BlueSpruce Investments Chicago, Illinois $631M AUM 11.83% 1-Year Est. Return
PWW
Pettyjohn Wood & White Lynchburg, Virginia $628M AUM 20.96% 1-Year Est. Return
TTSTC
Texas Treasury Safekeeping Trust Company Austin, Texas $628M AUM 15.58% 1-Year Est. Return
SWP
Summit Wealth Partners Orlando, Florida $632M AUM 9.71% 1-Year Est. Return
EIM
Essex Investment Management Boston, Massachusetts $632M AUM 95.36% 1-Year Est. Return

Sphera Funds Management's Q4 2019 Portfolio in Review

As of Q4 2019, Sphera Funds Management held 106 positions worth $1.21B, up 87% from $647M the previous quarter. Its ten largest holdings account for 61% of the portfolio.

Sphera Funds Management deployed $396M of net new capital in Q4 2019, opening 26 new positions and adding to 22 existing holdings. Its largest new stake was BioMarin Pharmaceuticals: 251,382 shares worth $21.3M.

By sector, the portfolio is most concentrated in Healthcare at 52% of assets, down from 74% a quarter earlier, followed by Technology and Industrials.

On the sell side, the largest reduction was Arqule Inc, an estimated $20.7M trimmed.

  • Sphera Funds Management's largest Q4 2019 buy was BioMarin Pharmaceuticals: 251,382 shares worth $21.3M.
  • Sphera Funds Management added most to Sanofi in Q4 2019, an estimated $20.6M increase.
  • Sphera Funds Management's biggest Q4 2019 reduction was Arqule Inc, cutting an estimated $20.7M.
  • Sphera Funds Management fully exited Celgene Corp in Q4 2019, selling an estimated $24.8M.
  • Sphera Funds Management's ten largest holdings make up 61% of its $1.21B portfolio in Q4 2019.
  • Sphera Funds Management opened 26 new positions and closed 20 in Q4 2019.
  • Sphera Funds Management's portfolio value rose 87% quarter-over-quarter to $1.21B.

Based on Sphera Funds Management's 13F filing for Q4 2019, filed 13 Feb 2020.